Clarus Therapeutics (CRXT) Tops Q4 EPS by 49c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
March 30, 2022 4:05 PM EDT2021 net revenue increased 119% year-over-year to $14.0 million
Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million
Fourth quarter 2021 total prescription growth for JATENZO® increased 11% sequentially and increased 81% year-over-year
Conference call and webcast today at 5:15 p.m. ET
NORTHBROOK, Ill., March 30, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results... More
